TTM
$19.3B
YoY change
+18.2%
5Y CAGR
+7.4%
Peak year (FY2022)
$24.2B
Cumulative EBITDA
$204B
EBITDA history chart for AbbVie (ABBV) from 2016 to 2025
Latest: $17.6B
EBITDA growth chart for AbbVie (ABBV) from 2016 to 2025
Latest: +18.2%
EBITDA history table for AbbVie (ABBV) from 2009 to 2025
| FY2025 | $17.6B | +18.2% | +$2.72B | ||
| FY2024 | $14.9B | -13.2% | -$2.26B | ||
| FY2023 | $17.2B | -29.0% | -$7B | ||
| FY2022 | $24.2B | +1.0% | +$241M | ||
| FY2021 | $23.9B | +94.2% | +$11.6B | ||
| FY2020 | $12.3B | +0.8% | +$96M | ||
| FY2019 | $12.2B | +47.1% | +$3.92B | ||
| FY2018 | $8.31B | -19.9% | -$2.07B | ||
| FY2017 | $10.4B | +2.5% | +$258M | ||
| FY2016 | $10.1B | +23.4% | +$1.92B | ||
| FY2015 | $8.2B | +128.8% | +$4.62B | ||
| FY2014 | $3.58B | -45.1% | -$2.94B | ||
| FY2013 | $6.53B | -6.5% | -$451M | ||
| FY2012 | $6.98B | +41.3% | +$2.04B | ||
| FY2011 | $4.94B | -17.9% | -$1.08B | ||
| FY2010 | $6.02B | +3.8% | +$221M | ||
| FY2009 | $5.8B | — | — |
- FY2025$17.6B+18.2%
- FY2024$14.9B-13.2%
- FY2023$17.2B-29.0%
- FY2022$24.2B+1.0%
- FY2021$23.9B+94.2%
- FY2020$12.3B+0.8%
- FY2019$12.2B+47.1%
- FY2018$8.31B-19.9%
- FY2017$10.4B+2.5%
- FY2016$10.1B+23.4%
- FY2015$8.2B+128.8%
- FY2014$3.58B-45.1%
- FY2013$6.53B-6.5%
- FY2012$6.98B+41.3%
- FY2011$4.94B-17.9%
- FY2010$6.02B+3.8%
- FY2009$5.8B—
EBITDA values are taken from AbbVie's reported income statements (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
About EBITDA at AbbVie (ABBV)
According to AbbVie's latest reported financial statements, the company's current EBITDA (TTM) is $19.3B. EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a common proxy for operating cash generation that strips out non-cash charges (depreciation and amortization) and capital structure effects (interest, taxes). Useful for comparing companies with different leverage and asset bases — see operating income and net income for fully GAAP figures.
Headline TTM above sums the four reported quarters through (reported ). Chart and table below cover the full reported history back to .
AbbVie (ABBV) most recent annual EBITDA stands at $17.6B (2025) – grew 18.2% year-over-year.
Over 2020–2025 (5 years), AbbVie EBITDA expanded at a +7.4% compound annual rate, with mixed annual results across the window.
AbbVie EBITDA declined from $24.2B in 2022 to $17.6B in 2025, a 27.1% drawdown.
$24.2B stands as the all-time-high annual EBITDA, posted in 2022, against a low of $3.58B during 2014.
AbbVie EBITDA by Year
AbbVie EBITDA 2025: $17.6B
2025's EBITDA for AbbVie came in at $17.6B, grew 18.2% from 2024.
AbbVie EBITDA 2024: $14.9B
AbbVie posted EBITDA of $14.9B in 2024, declined 13.2% below 2023.
AbbVie EBITDA 2023: $17.2B
In 2023, AbbVie reported EBITDA of $17.2B, declined 29.0% below 2022.
AbbVie EBITDA 2022: $24.2B
AbbVie EBITDA in 2022 was $24.2B, edged up 1.0% from 2021. This figure represents the highest annual value in the available history.
AbbVie EBITDA 2021: $23.9B
AbbVie EBITDA in 2021 was $23.9B.
See more financial history for AbbVie (ABBV).
Sector peers by EBITDA
Healthcare peers of AbbVie (ABBV), ranked by their latest EBITDA
| $41.1B | |
| $28.3B | |
| $27.9B | |
| $24.4B | |
| $23.1B | |
| $19.8B | |
| $16.9B | |
| $11.5B |
- $41.1B
- $28.3B
- $27.9B
- $24.4B
- $23.1B
- $19.8B
- $16.9B
Frequently asked questions
AbbVie (ABBV) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation
How this company returns cash to shareholders — buybacks, dividends, and stock splits.